Know Cancer

or
forgot password

Safety and Efficacy of Cannabidiol for Grade I/II Acute Graft Versus Host Disease (GVHD) After Allogeneic Stem Cell Transplantation


Phase 1/Phase 2
18 Years
N/A
Open (Enrolling)
Both
Graft Versus Host Disease

Thank you

Trial Information

Safety and Efficacy of Cannabidiol for Grade I/II Acute Graft Versus Host Disease (GVHD) After Allogeneic Stem Cell Transplantation


Inclusion Criteria:



1. Patients over 18 years

2. Acute GVHD grade I/II

3. No history of psychosis

4. Signed informed concent

Exclusion Criteria:

1. Acute GVHD grade > II

2. History of psychosis

3. History of asthma

Type of Study:

Interventional

Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Complete resolution of acute GVHD

Outcome Time Frame:

within 90 days from start of therapy

Safety Issue:

No

Principal Investigator

Moshe Yeshurun, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Davidoff cancer center, Beilinson hospital, Rabin Medical Center

Authority:

Israel: Ethics Commission

Study ID:

0388-11-RMC

NCT ID:

NCT01596075

Start Date:

July 2012

Completion Date:

Related Keywords:

  • Graft Versus Host Disease
  • Cannabidiol
  • GVHD
  • Allogeneic transplantation
  • Graft vs Host Disease

Name

Location